Philips Respironics Announces Availability of New Patient-Centric Solution for the Management of Chronic Respiratory

Philips Respironics Announces Availability of New Patient-Centric Solution for
 the Management of Chronic Respiratory Insufficiency Diseases, BiPAP A40, on
                             World COPD Day 2012

  PR Newswire

  DÜSSELDORF, Germany, November 14, 2012

DÜSSELDORF, Germany, November 14, 2012 /PRNewswire/ --

BiPAP A40 is a new multi-modality bi-level ventilator featuring the first
fully automatic ventilation mode, designed to support the smooth transition of
treatment from hospital to home

Philips Respironics today announces the availability of the new bi-level
ventilator BiPAP A40 ^[1] for the management of chronic respiratory
insufficiency, a condition secondary to diseases such as obesity
hypoventilation syndrome, chronic obstructive pulmonary disease (COPD) and
neuromuscular disease for adult and pediatric patients (above 10 kg).

Launching on World COPD Day 2012 and being showcased this week at Medica 2012,
the world's largest medical trade fair, the BiPAP A40 improves the management
of chronic respiratory diseases by offering a range of unique benefits that
facilitate the smoothest possible transition in the patient care pathway -
from initial titration to hospital discharge, from home therapy to long-term
follow-up. 

"Philips is proud to be able to provide access to new and innovative solutions
that improve quality of care for respiratory patients - both in hospital and
at home," comments Mats Dahlquist, general manager international, Philips Home
Healthcare Solutions.

"One of the key benefits of the BiPAP A40 is an innovative ventilation mode
called AVAPS-AE, which helps to guide clinicians during the initial titration
of therapy, while maintaining comfort and improving efficacy for the patient.
This new ventilation mode automatically maintains airway patency while
delivering the correct level of ventilation each user requires, whatever their
body position or sleep stage. AVAPS-AE mode also helps to guide clinicians
during the initial titration of therapy, while providing long term comfort and
assuring therapy compliance.

In addition to the introduction of AVAPS-AE, the BiPAP A40 features a unique
battery module design which provides users with an enhanced level of autonomy
that increases support when traveling, or in the case of a power shortage.
Furthermore, the design incorporates an intuitive user interface and data
management tools that allow clinicians to remotely access and review data
about a user's therapy, adjusting it as necessary. This can help to reduce
therapy drop out and the associated risk of hospital re-admission.

Although many chronic respiratory diseases are preventable and can be
effectively managed, they continue to be an important cause of morbidity,
mortality and the increased health care costs worldwide. COPD is predicted to
become the third leading cause of death worldwide by 2030, with 65 million
people currently living with the disease across the world. ^[i] COPD is a
particularly costly disease to manage, with an annual healthcare bill of more
than 10 billion Euros across the EU alone. ^[ii]

Philips Respironics holds leading positions in the fast-growing areas of
respiratory care, non-invasive ventilation and sleep management and is
currently funding three large European trials investigating the effects of
home non-invasive ventilation in patients with COPD and obesity
hypoventilation syndrome (OHS). 

--------------------------------------------------

1. Not available for sale in the U.S.A.

To find out more about BiPAP A40, please visit http://www.philips.com/BiPAP
A40

About Royal Philips Electronics

Royal Philips Electronics (NYSE: PHG, AEX: PHIA) is a diversified health and
well-being company, focused on improving people ' s lives through meaningful
innovation in the areas of Healthcare, Consumer Lifestyle and Lighting.
Headquartered in the  Netherlands , Philips posted 2011 sales of EUR 22.6
billion and employs approximately 121,000 employees with sales and services in
more than 100 countries. The company is a leader in cardiac care, acute care
and home healthcare, energy efficient lighting solutions and new lighting
applications, as well as male shaving and grooming, home and portable
entertainment and oral healthcare. News from Philips is located at
http://www.philips.com/newscenter .

i. World Health Organization. Burden of COPD.
http://www.who.int/respiratory/copd/burden/en/index.html . Accessed 26 October
2012

ii. Wouters EFM. Economic analysis of the confronting COPD survey: an overview
of results.Respir Med2003; 97:S3-S14.

Contact: For further information, please contact: Sabine van Deursen, Philips
Healthcare Communications, Tel: +31(0)6-1504-3894, E-mail:
sabine.van.deursen@philips.com. Manuela Leurent, Philips Home Healthcare, Tel:
+33-6-80-00-61-25, E-mail: manuela.leurent@philips.com.